SEC For	rm 4																
	FORM	4	UNITE	D STA	TES						NGE C	OMMI	SSION				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STA		Washington, D.C. 20549 NT OF CHANGES IN BENEFICIAL OWNEF d pursuant to Section 16(a) of the Securities Exchange Act of 1934								HIP	OMB Estim	OMB APPROVAL OMB Number: 3235- Estimated average burden hours per response:		
Check transac contrac the pure securit to satis conditi	this box to indi ction was made ct, instruction o rchase or sale o	pursuant to a written plan for of equity r that is intended ve defense								mpany Act							
1. Name and Address of Reporting Person* Sayad Pierre Sargis					2. Issuer Name and Ticker or Trading Symbol <u>FENNEC PHARMACEUTICALS INC.</u> [FENC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
(Last)(First)(Middle)C/O FENNEC PHARMACEUTICALS, INC.PO BOX 13628, 68 TW ALEXANDER DRIVE				3	3. Date of Earliest Transaction (Month/Day/Year) 11/13/2024								below) below) Chief Medical Officer				
(Street) RESEARCH TRIANGLE NC PARK			27709	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) ✓ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	tate)	(Zip)	<u> </u>				<u> </u>	<u> </u>	<u> </u>		<u> </u>					
Iable I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transi Date (Month/I					Execution Date, Transaction Disposed Of (D) (Instr. 3,						d (A) or	or and 5) Securities Beneficially Owned Following (I) (Instr. 4)			7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) oi (D)	Price	Transacti (Instr. 3 a	on(s)				
			Table II -							osed of, convertit			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	ate, Trar Cod	, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			d Amount ies g Security nd 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershij (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
	\$4.23	11/13/2024		A		150,000	1	11/13/2025	.(2)	11/13/2034	Common	150,000	\$4.23	150,0	00	D	

1. On November 13, 2024, Pierre Sayad was granted incentive stock options to purchase 150,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.

2. One-third of the shares subject to this option may be exercised as of November 13, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date until all shares have vested.

 /s/ Pierre Sayad
 11/13/2024

 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.